← Back to Clinical Trials
Recruiting Phase 1 NCT06818864

DBS for Cognitive Deficits After Traumatic Brain Injury

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition TBI Traumatic Brain Injury
Sponsor Sunnybrook Health Sciences Centre
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 10
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2024-11-01
Completion 2026-11-01
Interventions
Deep Brain Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Patients with memory and cognitive deficits following TBI that do not respond to conventional treatments experience a decrease in quality of life. Despite advances in neuroimaging, genetics, pharmacology and psychosocial interventions in the last half century, little progress has been made in altering the natural history of the condition or its outcome. This study would explore whether a surgical therapy is safe and potentially effective in patients who develop refractory memory and cognitive deficits following TBI. Preclinical studies suggest that DBS may improve memory deficits in TBI models. Moreover, DBS delivered to the fornix has shown promising clinical results in patients with Alzheimer's disease. The main mechanism for the improvements induced by DBS in memory tests is the development of multiple forms of plasticity.

Eligibility Criteria

Inclusion Criteria: 1. Female or male patients between age 18-70. 2. Diagnosis of memory and cognitive deficits in patients who suffered TBI will be defined according to the Diagnostic and Statistical Manual 5th edition (DSM-5). 3. Patients with cognitive disorder not otherwise specified, dementia, or amnestic disorder due to TBI will be considered. 4. Performance at least 1.5 standard deviations below the estimated premorbid intelligence (assessed by the American National Adult Reading Test) on memory tests (assessed by the California Verbal Learning Test; CVLT). 5. History of TBI for at least 1 year, preferably with evidence of failure to donepezil, cholinesterase inhibitors and cognitive therapy. 6. Ability to provide informed consent and comply with all testing, follow-ups and study appointments. Exclusion Criteria: 1. Active neurologic disease, such as epilepsy or Alzheimer's disease. 2. Any contraindication to magnetic resonance imaging (MRI) scanning. 3. Presence of clinical and

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}